Drugs / F18-AV45
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04174287 | Mar 2019 → Mar 2023 | Alzheimer disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03430869 | Mar 2018 → Dec 2021 | major depressive disorder | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01624389 | Jan 2012 → Jan 2015 | Alzheimer disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-07-22 | Eli Lilly and Company | Results New Study Shows Florbetapir F 18 Injection Scans Led to Change in Diagnosis and Management of Patients Being Evaluated for Cognitive Decline lilly.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-07-22 | Eli Lilly and Company | New Study Shows Florbetapir F 18 Injection Scans Led to Change in Diagnosis and Management of Patients Being Evaluated for Cognitive Decline lilly.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 AV-45 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03430869 ↗ |
| Modality | Diagnostic / imaging agent | “Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.” NCT03430869 ↗ |